Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis.

Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B.

MBio. 2012 Oct 2;3(5). pii: e00312-12. doi: 10.1128/mBio.00312-12. Print 2012.

2.

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, Miller PE, Boscoe BP, Cox ED, Iwata KK, Jani JP, Provoncha K, Kath JC, Liu Z, Moyer JD.

Cancer Res. 2003 Aug 1;63(15):4450-9.

3.

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):739-48.

PMID:
10525095
4.

Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.

Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y.

EMBO J. 1998 Oct 15;17(20):5948-63.

5.

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P.

Cancer Res. 1997 Nov 1;57(21):4838-48.

6.

erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.

Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, DiOrio CI, Barbacci EG, Miller PE, et al.

J Med Chem. 1995 Sep 15;38(19):3813-20.

PMID:
7562912
7.

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.

Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al.

J Med Chem. 1995 Sep 15;38(19):3806-12.

PMID:
7562911
8.

The structural basis for the specificity of epidermal growth factor and heregulin binding.

Barbacci EG, Guarino BC, Stroh JG, Singleton DH, Rosnack KJ, Moyer JD, Andrews GC.

J Biol Chem. 1995 Apr 21;270(16):9585-9. Erratum in: J Biol Chem 1995 Nov 24;270(47):28494.

Supplemental Content

Loading ...
Support Center